Literature DB >> 26629287

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629287      PMCID： PMC4665056     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  4 in total

1.  Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota.

Authors:  Kurtis B Reed; Jerry D Brewer; Christine M Lohse; Kariline E Bringe; Crystal N Pruitt; Lawrence E Gibson
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

2.  Incidence of childhood and adolescent melanoma in the United States: 1973-2009.

Authors:  Jeannette R Wong; Jenine K Harris; Carlos Rodriguez-Galindo; Kimberly J Johnson
Journal:  Pediatrics       Date:  2013-04-15       Impact factor: 7.124

Review 3.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

4.  Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.

Authors:  Keith L Davis; Debanjali Mitra; Srividya Kotapati; Ramy Ibrahim; Jedd D Wolchok
Journal:  Appl Health Econ Health Policy       Date:  2009       Impact factor: 2.561
  4 in total
  44 in total

1.  Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.

Authors:  Matthias Pauthner; Jenny Yeung; Chris Ullman; Joost Bakker; Thierry Wurch; Janice M Reichert; Fridtjof Lund-Johansen; Andrew R M Bradbury; Paul J Carter; Joost P M Melis
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 2.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

Review 3.  Thyroid dysfunctions secondary to cancer immunotherapy.

Authors:  P Chalan; G Di Dalmazi; F Pani; A De Remigis; A Corsello; P Caturegli
Journal:  J Endocrinol Invest       Date:  2017-12-13       Impact factor: 4.256

Review 4.  B7-H3 role in the immune landscape of cancer.

Authors:  Jose R Castellanos; Ian J Purvis; Collin M Labak; Maheedhara R Guda; Andrew J Tsung; Kiran K Velpula; Swapna Asuthkar
Journal:  Am J Clin Exp Immunol       Date:  2017-06-15

Review 5.  Immune checkpoint pathways in non-small cell lung cancer.

Authors:  Young Kwang Chae; Ayush Arya; Wade Iams; Marcello Cruz; Nisha Mohindra; Victoria Villaflor; Francis J Giles
Journal:  Ann Transl Med       Date:  2018-03

Review 6.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

7.  Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Mahdi Zargar; Thomas McFarlane; Kelvin K W Chan; William W L Wong
Journal:  Oncologist       Date:  2017-10-11

Review 8.  Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer.

Authors:  Zachary R Stephen; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2020-11-25       Impact factor: 9.933

9.  Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study.

Authors:  Helena Pópulo; Beatriz Domingues; Cristina Sampaio; José Manuel Lopes; Paula Soares
Journal:  J Exp Pharmacol       Date:  2021-05-24

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.